Hepatoprotective Potential of JHB, a Functional Beverage, in a Mouse Model of Acute Alcohol-Induced Liver Injury

Why It Matters

JHB demonstrates a food‑grade strategy to curb acute alcohol‑induced liver injury, opening a nutraceutical market for binge‑drinking consumers and supporting broader public‑health efforts.

Key Takeaways

• JHB contains 20 identified flavonoids, including dihydromyricetin and quercetin‑3‑glucoside.
• High‑dose JHB reduced ALT and AST by over 40% versus alcohol‑only mice.
• Antioxidant enzymes SOD, GSH and CAT were restored to near‑normal levels.
• Pro‑inflammatory cytokines TNF‑α, IL‑1β, IL‑6, and IL‑4 dropped significantly.
• ADH and ALDH activities increased dose‑dependently, enhancing ethanol clearance.

Pulse Analysis

Alcohol‑related liver injury remains a leading cause of morbidity worldwide, driven by rising binge‑drinking patterns and limited therapeutic options beyond abstinence. Consumers are increasingly turning to functional foods and beverages that claim liver‑supporting benefits, creating a multi‑billion‑dollar market for nutraceuticals. Within this landscape, plant‑derived flavonoids have attracted scientific attention for their antioxidant, anti‑inflammatory, and metabolic‑modulating properties, positioning them as natural candidates to counteract ethanol‑induced oxidative stress and cytokine storms.

The JHB formulation leverages a blend of hawthorn, apple, *Ampelopsis grossedentata* leaf extract, and pueraria, delivering a cocktail of twenty flavonoids such as dihydromyricetin, rutin, and quercetin‑3‑glucoside. These compounds are known to activate the Nrf2 antioxidant pathway, inhibit CYP2E1‑mediated ROS production, and stabilize cell membranes. In the mouse model, JHB not only normalized transaminases but also amplified ADH and ALDH activities, suggesting enhanced ethanol clearance. Compared with the benchmark hepatoprotective agent silymarin, JHB achieved comparable histological recovery, indicating that a beverage format can match traditional herbal extracts in efficacy.

For industry stakeholders, the study provides a pre‑clinical proof point that could accelerate product development and regulatory filing under the “food for special medical purposes” category. Scaling production will require consistent flavonoid profiling and stability testing, while clinical trials must confirm dose translation and safety in humans. If validated, JHB‑type drinks could become a differentiated offering in retail pharmacies, online health stores, and hospitality venues, catering to consumers seeking proactive liver support without prescription medication.